|
|
|
On episode 125 of Cell & Gene: The Podcast, host Erin Harris speaks with Halloran Consulting Group’s Monika Swietlicka on FDA flexibility in cell and gene therapy — using a risk‑based, holistic approach without lowering evidentiary standards. |
|
|
|
|
|
|
|
|
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
| Connect With Life Science Leader: |
|
|
|